Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorVertero Therapeutics

About this trial

This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.

Eligibility criteria

Qualifiers

Between 18-80 years of age at ICF signing (inclusive)

A diagnosis of PD within 10 years from the time of ICF signing

Current or history of gastrointestinal (GI) dysfunction or constipation based on screening assessment

All participants must understand and provide written informed consent prior to any study specific procedures

Disqualifiers

Any known GI disorder if deemed clinically significant by the investigator. GI disorders may include, but are not limited to: Crohn's disease, ulcerative colitis, celiac disease, irritable bowel syndrome, or lactose intolerance

Recent GI infection in the past 3 months if deemed clinically significant by the investigator.

Major GI surgery (excluding appendectomy/cholecystectomy), such as bariatric surgery, gastrectomy, esophagectomy, vagotomy, small intestine surgeries, any type of colectomy, colostomy and anorectal surgeries if deemed clinically significant by the investigator

Any known current or past eating disorder if deemed clinically significant by the investigator

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators